Shares of biopharmaceutical company Selecta Biosciences (NASDAQ:CELB) are trending today after it announced positive topline results from a Phase 3 study evaluating the safety and efficacy of SEL-212 in chronic refractory gout patients at different doses.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The U.S. as well as the global leg of the study met its primary endpoint. Importantly, response rates stood at 56% and 47% respectively in both legs of the study.
Next, the company is setting sights on the commercialization of SEL-212 and expects to file a marketing authorization application in the U.S. in H1 2024.
Overall, Wall Street has a consensus price target of $6.29 on CELB, implying a whopping 391.4% potential upside in the stock. That’s on top of an 11.3% gain in the share price so far this year.
Read full Disclosure
